The 2010s saw major strides made through several large-scale initiatives aimed at mapping the human proteome and developing approaches for clinical work.
The researchers combined genomic, transcriptomic, and proteomic profiling to gain insight into the basic biology and possible treatments for the disease.
The DoD and VA-led initiative is moving beyond its initial focus on lung cancer to add analyses of multiple cancer types and a prospective, multisite study.
The ability to effectively use FFPE tissue opens up a large number of clinical samples for analysis, many with quality data on patient demographics, treatment, and outcomes.
The researchers used a combination of genomic, transcriptomic, and proteomic analyses to study mechanisms of resistance to the pan-PI3K inhibitor buparlisib.
Called LinkedOmics, the resource features three modules for analyzing multi-omic data collected in projects encompassing 11,158 patients and 32 cancer types.
The organization named the institutions that will be performing the proteomic and proteogenomic analyses planned to for the five-year, $65 million effort.
